Key Highlights

  • PepGen (NASDAQ:PEPG) finished Tuesday, November 10, 2026 at USD 6.21, a rise of 159.83% from a calculated prior close of USD 2.39, placing it among the biggest gainers in a published screener snapshot covering 4,625 names.
  • Some 67.27 million shares traded at a relative Volume of 65.22, pointing to a recent average of roughly 1.03 million shares (calculated), and close to USD 417.7 million in stock changed hands at the closing price (calculated).
  • The same snapshot lists a Market Value of USD 165.53 million, a trailing diluted EPS of USD -1.31, EPS growth of +56.00%, no P/E ratio and a 0.00% dividend yield.
  • Nothing in a company release, a filing or published coverage dated November 9 or November 10, 2026 could be found, so the jump is treated as lacking an identified catalyst.

What Drove PepGen on November 10 (+159.83%)

PepGen is a Boston-based clinical-stage biotechnology firm, established in 2018, whose oligonucleotide therapeutics target serious neuromuscular and neurologic conditions. It has 56 staff. The stock closed Tuesday at USD 6.21, a gain of 159.83%. Arithmetic on those two published figures points to a prior close near USD 2.39 on Monday, November 9, 2026, which is about USD 3.82 per share of upside in one session. A quote published on November 3, 2026 read USD 2.40, with a day range of USD 2.36 to USD 2.45 and just 27.06 thousand shares traded versus an average of 1.16 million. Against that average, Tuesday's 67.27 million shares is about 58 times larger (calculated).

The Rationale: No Catalyst Identified in Published Coverage

Two rounds of searching turned up no company release, 8-K or published coverage dated November 9 or November 10, 2026 that would account for the surge, so published coverage leaves the cause unidentified. As general context, a rise beyond 100% in a clinical-stage biotech tends to trace back to something like trial data, a regulatory development, a partnering or licensing agreement, a Takeover approach, or an Equity raise priced at a premium. Short covering and retail buying can amplify a spike. None of these has been confirmed for PepGen (NASDAQ:PEPG), and an unexplained rally carries its own hazard, since it can unwind fast when no news arrives.

Valuation, Liquidity and Risks for PepGen

The snapshot's market value of USD 165.53 million lines up with the November 3 quote of USD 166.22 million at USD 2.40, so it seems to reflect the older price. That works out to roughly 69.3 million shares (calculated). Applied to USD 6.21, the same share count would be worth about USD 430 million (calculated), so size figures should be viewed as unconfirmed. On November 3 the 52-week range ran from USD 1.31 to USD 7.80, leaving USD 6.21 near 80% of the high and 4.74 times the low. The company has no profit, a P/E near -1.8 and a trailing loss of USD 1.31 per share, so value leans on pipeline hopes. Clinical-stage firms frequently sell new equity after sharp rallies, diluting existing holders, and a jump of this scale gives no assurance of more to come.

Where Things Stand

The reason PepGen (NASDAQ:PEPG) leapt 159.83% on November 10, 2026 is that no catalyst appears in published coverage. The shares ended at USD 6.21 on 67.27 million traded, roughly 65 times the recent average, and sit close to the USD 7.80 peak of the 52-week range. A surge on this much volume without a disclosed reason can reverse, and any Capital raise would dilute shareholders.